198 related articles for article (PubMed ID: 22087794)
1. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Jianu CS; Lange OJ; Viset T; Qvigstad G; Martinsen TC; Fougner R; Kleveland PM; Fossmark R; Hauso Ø; Waldum HL
Scand J Gastroenterol; 2012 Jan; 47(1):64-7. PubMed ID: 22087794
[TBL] [Abstract][Full Text] [Related]
2. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
3. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
[TBL] [Abstract][Full Text] [Related]
4. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
[TBL] [Abstract][Full Text] [Related]
5. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
6. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
7. A gastric neuroendocrine tumor after prolonged use of proton pump inhibitors.
Prado PHT; Paula RV; de Faria ATR; Silva BL; Ardengh JC
Rev Esp Enferm Dig; 2023 Apr; 115(4):209-210. PubMed ID: 36148661
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
9. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
[TBL] [Abstract][Full Text] [Related]
10. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
11. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia.
Waldum HL; Rehfeld JF
Scand J Gastroenterol; 2019 Sep; 54(9):1118-1123. PubMed ID: 31524029
[TBL] [Abstract][Full Text] [Related]
13. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
14. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
15. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin].
Kim BW; Lee BI; Kim HK; Cho YS; Chae HS; Lee HK; Kim HJ; Han SW
Korean J Gastroenterol; 2009 Feb; 53(2):84-9. PubMed ID: 19237833
[TBL] [Abstract][Full Text] [Related]
16. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Tsukamoto H; Mizoshita T; Sasaki M; Mizushima T; Tanida S; Ozeki K; Hirata Y; Shimura T; Kataoka H; Kamiya T; Nojiri S; Tsukamoto T; Tatematsu M; Joh T
Asian Pac J Cancer Prev; 2011; 12(4):1049-54. PubMed ID: 21790250
[TBL] [Abstract][Full Text] [Related]
17. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
18. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
19. Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy.
Anjiki H; Mukaisho KI; Kadomoto Y; Doi H; Yoshikawa K; Nakayama T; Vo DT; Hattori T; Sugihara H
Clin J Gastroenterol; 2017 Apr; 10(2):128-136. PubMed ID: 28160247
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis.
Fujimoto K; Hongo M;
Intern Med; 2011; 50(3):179-88. PubMed ID: 21297318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
